Adial Pharmaceuticals’ (ADIL) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of Adial Pharmaceuticals (NASDAQ:ADIL) in a report released on Friday morning,Weiss Ratings reports.

ADIL has been the subject of a number of other reports. Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a report on Saturday, July 26th. Zacks Research cut shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Finally, Maxim Group upgraded shares of Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a report on Tuesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $4.75.

Adial Pharmaceuticals Price Performance

Adial Pharmaceuticals stock opened at $0.36 on Friday. The firm has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.47. The stock has a market capitalization of $7.92 million, a PE ratio of -0.35 and a beta of 1.36. Adial Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $1.30.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.04. On average, analysts forecast that Adial Pharmaceuticals will post -1.53 earnings per share for the current fiscal year.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.